RapidAI empowers clinicians to make accurate diagnostic and treatment decisions for stroke and aneurysm patients.
RapidAI has raised $75.0M in total funding. The most recent round was Series C. The last funding was announced in July 2023.
RapidAI's investors include Vista Credit Partners, Lennertz & Co..
RapidAI is headquartered in Menlo Park, United States.
RapidAI empowers clinicians to make accurate diagnostic and treatment decisions for stroke and aneurysm patients.
RapidAI is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RapidAI — Funding & Investors." VCBacked, July 27, 2023, https://www.vcbacked.co/company/rapidai. Accessed August 1, 2026.
VCBacked. (2023). RapidAI — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/rapidai
{{cite web |title=RapidAI — Funding & Investors |url=https://www.vcbacked.co/company/rapidai |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated